These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 29861296)
1. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. McBride MJ; Pulice JL; Beird HC; Ingram DR; D'Avino AR; Shern JF; Charville GW; Hornick JL; Nakayama RT; Garcia-Rivera EM; Araujo DM; Wang WL; Tsai JW; Yeagley M; Wagner AJ; Futreal PA; Khan J; Lazar AJ; Kadoch C Cancer Cell; 2018 Jun; 33(6):1128-1141.e7. PubMed ID: 29861296 [TBL] [Abstract][Full Text] [Related]
2. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction. Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620 [TBL] [Abstract][Full Text] [Related]
3. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Kadoch C; Crabtree GR Cell; 2013 Mar; 153(1):71-85. PubMed ID: 23540691 [TBL] [Abstract][Full Text] [Related]
4. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier. Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495 [TBL] [Abstract][Full Text] [Related]
5. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784 [TBL] [Abstract][Full Text] [Related]
6. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability. Benabdallah NS; Dalal V; Scott RW; Marcous F; Sotiriou A; Kommoss FKF; Pejkovska A; Gaspar L; Wagner L; Sánchez-Rivera FJ; Ta M; Thornton S; Nielsen TO; Underhill TM; Banito A Nat Struct Mol Biol; 2023 Nov; 30(11):1640-1652. PubMed ID: 37735617 [TBL] [Abstract][Full Text] [Related]
7. The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies. Boulay G; Cironi L; Garcia SP; Rengarajan S; Xing YH; Lee L; Awad ME; Naigles B; Iyer S; Broye LC; Keskin T; Cauderay A; Fusco C; Letovanec I; Chebib I; Nielsen PG; Tercier S; Cherix S; Nguyen-Ngoc T; Cote G; Choy E; Provero P; Suvà ML; Rivera MN; Stamenkovic I; Riggi N Life Sci Alliance; 2021 Feb; 4(2):. PubMed ID: 33361335 [TBL] [Abstract][Full Text] [Related]
8. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell; ; . PubMed ID: 22439931 [TBL] [Abstract][Full Text] [Related]